Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has earned an average recommendation of “Moderate Buy” from the eleven ratings firms that are currently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $44.50.

A number of brokerages recently issued reports on CLDX. The Goldman Sachs Group increased their price target on shares of Celldex Therapeutics from $30.00 to $34.00 and gave the stock a “neutral” rating in a report on Monday, March 2nd. Barclays lifted their price objective on shares of Celldex Therapeutics from $21.00 to $24.00 and gave the company an “underweight” rating in a report on Wednesday, December 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Wednesday, January 21st. Finally, Stifel Nicolaus reissued a “buy” rating and set a $68.00 target price (up from $58.00) on shares of Celldex Therapeutics in a research note on Thursday, February 26th.

Celldex Therapeutics Trading Up 2.9%

Shares of CLDX stock opened at $30.90 on Monday. Celldex Therapeutics has a twelve month low of $14.40 and a twelve month high of $31.99. The stock has a market cap of $2.06 billion, a P/E ratio of -7.94 and a beta of 1.17. The stock has a 50 day moving average of $26.64 and a 200 day moving average of $26.27.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Wednesday, February 25th. The biopharmaceutical company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($1.00) by ($0.22). The company had revenue of $0.12 million during the quarter, compared to analysts’ expectations of $1.53 million. Celldex Therapeutics had a negative return on equity of 41.67% and a negative net margin of 3,446.88%. On average, research analysts predict that Celldex Therapeutics will post -2.48 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Celldex Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Aster Capital Management DIFC Ltd purchased a new stake in shares of Celldex Therapeutics in the third quarter valued at approximately $26,000. Wilmington Savings Fund Society FSB purchased a new position in shares of Celldex Therapeutics during the 3rd quarter valued at approximately $42,000. Russell Investments Group Ltd. lifted its position in shares of Celldex Therapeutics by 27.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 501 shares in the last quarter. Quantbot Technologies LP acquired a new stake in Celldex Therapeutics in the 3rd quarter valued at $63,000. Finally, Strs Ohio acquired a new stake in Celldex Therapeutics in the 3rd quarter valued at $75,000.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.